Deal Details

Apellis Completes $403 Million Follow-On Offering

Healthcare

Apellis follow-on offering

Summary

Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 8,563,830 shares of its common stock at a public offering price of $47.00 per share, for total gross proceeds of $403 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. The offering included the exercise in full by the underwriters of their option to purchase an additional 1,117,021 shares of common stock.

Baird served as a co-manager on this offering.

About

Apellis is a global biopharmaceutical company that is committed to leveraging courageous science, creativity and compassion to deliver life-changing therapies. Leaders in complement, Apellis ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. Apellis is advancing this science to continually develop transformative medicines for people living with rare, retinal and neurological diseases. Apellis Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.

Healthcare

Apellis follow-on offering